United States · Cost

Wegovy cost and coverage in the US

Pending medical review

Applies to: United States

By Joshua Nichvolodoff · Fact-checked against sources November 2, 2026 · Next review due January 31, 2027

Clinical review: not yet reviewed by a clinician. How review works · Editorial policy

Wegovy now comes as an injectable pen and a daily pill, each with published self-pay prices, plus a copay card, a TrumpRx price, and a new Medicare program. Here is what each source says, dated and linked.

Self-pay through Novo Nordisk

Novo Nordisk's April 2026 Wegovy price guide lists the pen at $349 a month (as reported by Novo Nordisk (NovoCare), April 2026; checked November 2, 2026 — may have changed)[1], the higher-dose Wegovy HD pen at $399 a month (as reported by Novo Nordisk (NovoCare), April 2026; checked November 2, 2026 — may have changed)[1], and the pill at $149 / $199 / $299 / $299 a month by dose (as reported by Novo Nordisk (NovoCare), April 2026; checked November 2, 2026 — may have changed)[1]. For new patients it lists $199 a month (as reported by Novo Nordisk (NovoCare), April 2026; checked November 2, 2026 — may have changed)[1]. NovoCare says self-pay purchases will not count toward your insurance out-of-pocket limits or deductible[4].

If your insurance covers Wegovy

The savings offer for commercially insured people lists as little as $25 a month, with savings capped at $100 a month (as reported by Novo Nordisk (NovoCare), April 2026; checked November 2, 2026 — may have changed)[1]; government beneficiaries are excluded. See savings cards, explained.

TrumpRx

The White House says injectable Wegovy is available through TrumpRx.gov at an average of $350 a month, as low as $199 (as reported by The White House, February 5, 2026; checked November 2, 2026 — may have changed)[5], and the pill at as low as $149 a month (as reported by The White House, February 5, 2026; checked November 2, 2026 — may have changed)[5].

Medicare

By law, Medicare Part D excludes drugs used specifically for obesity; after Wegovy was approved to reduce cardiovascular risk, Part D plans can cover it for that use[2]. CMS says plans must keep covering Wegovy for that use[6].

Separately, the Medicare GLP-1 Bridge is a CMS demonstration giving eligible Part D enrollees certain GLP-1 drugs for weight management at $50 copay a month (as reported by Medicare.gov (Centers for Medicare & Medicaid Services), July 1, 2026; checked November 2, 2026 — may have changed)[3]. Eligibility depends on BMI and certain health conditions, and a prescriber must certify use[3]. It was extended to the end of 2027[7].

List price

The White House cited monthly list prices of Ozempic $1,028; Wegovy $1,349; Zepbound $1,088 a month (as reported by The White House, February 5, 2026; checked November 2, 2026 — may have changed)[5]. Novo Nordisk says list prices fall to $675 a month[8] from January 1, 2027[8].

Prices change; every figure is dated. General information, not medical or financial advice. Light Years earns nothing from any product named here.

Sources

  1. Wegovy price guide (self-pay and commercial copay). Novo Nordisk (NovoCare), April 2026. https://www.novocare.com/content/dam/novonordisk/novocare/redesign/pdf/Wegovy_Price_Guide.pdf. Accessed November 2, 2026. Back to the text
  2. A new use for Wegovy opens the door to Medicare coverage for millions of people with obesity. KFF, April 24, 2024. https://www.kff.org/medicare/issue-brief/a-new-use-for-wegovy-opens-the-door-to-medicare-coverage-for-millions-of-people-with-obesity/. Accessed November 2, 2026. Back to the text
  3. Weight loss drugs (Medicare GLP-1 Bridge). Medicare.gov (Centers for Medicare & Medicaid Services). https://www.medicare.gov/glp1bridge. Accessed November 2, 2026. Back to the text
  4. Price your Wegovy. Novo Nordisk (NovoCare). https://www.novocare.com/obesity/products/wegovy.html. Accessed November 2, 2026. Back to the text
  5. Fact sheet: President Donald J. Trump launches TrumpRx.gov to bring lower drug prices to American patients. The White House, February 5, 2026. https://www.whitehouse.gov/fact-sheets/2026/02/fact-sheet-president-donald-j-trump-launches-trumprx-gov/. Accessed November 2, 2026. Back to the text
  6. Medicare GLP-1 Bridge: expectations and FAQs (memo to Part D plan sponsors). Centers for Medicare & Medicaid Services, June 10, 2026. https://www.cms.gov/files/document/medicare-glp-1-bridge-expectations-faqs.pdf. Accessed November 2, 2026. Back to the text
  7. CMS extends Medicare's short-term bridge program for GLP-1 obesity drug coverage. KFF, April 23, 2026. https://www.kff.org/quick-take/cms-extends-medicares-short-term-bridge-program-for-glp-1-obesity-drug-coverage/. Accessed November 2, 2026. Back to the text
  8. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic and Rybelsus. Novo Nordisk, February 24, 2026. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916504. Accessed November 2, 2026. Back to the text

Figures marked “as reported” are historical: they show what the source said on that date, not today's price or rule.

Changes to this page

  • — First published.

Substantive corrections are also logged at corrections.

← More in Cost & coverage